Executive Summary
ESC Congress 2026 delivered two practice-relevant reads on TAVI periprocedural care and one meta-analytic shrug on PCI sequencing: POPular ACE TAVI showed routine protamine after transfemoral TAVI cut the composite of death and clinically relevant bleeding from 29.4% to 18.5% (N=1,000), driven entirely by minor bleeds with no mortality or major-bleed signal, while a 3-RCT meta-analysis (n=1,156) found PCI in TAVI candidates did not reduce death or MI but did lower stroke (OR 0.68). A separate ESC-presented sequencing analysis reported TAVI-before-PCI noninferior to concurrent strategies. Together the day tightens the operational case for routine heparin reversal and loosens the argument that revascularization must precede or accompany TAVI in most anatomies.
- POPular ACE TAVI: routine protamine cut clinically relevant bleeding 18.3% vs 29.2% with one anaphylaxis event and no anaphylaxis deaths (TCTMD).
- Meta-analysis of PCI in TAVI candidates: no mortality or MI benefit, stroke reduction (OR 0.68, 95% CI 0.48–0.95), bleeding trend upward (Cardiology in Review).
- Single-center TAVI series (N=1,476): abandoning routine femoral protection wire cut vascular complications from 18.6% to 10.8% (Clinical Research in Cardiology).
- Systematic review of 1,637 AS+ATTR-CA patients: TAVI 30-day mortality comparable to isolated AS, but higher AKI, pacemaker rates, and late HF readmissions (EJHF).
- ESC-presented tricuspid repair data: transcatheter TR intervention reduced death and HF hospitalization in severe TR (Medscape).
What to watch: Remaining ESC Congress late-breakers through September 2 and simultaneous journal releases on tricuspid transcatheter therapy that could reinforce the ESC 2025 Class IIa recommendation.
Aortic Valve (TAVR/TAVI)
The day's TAVI signal is periprocedural, not durability — and the periprocedural news is mostly favorable to transfemoral operators. POPular ACE TAVI (N=1,000, ESC-presented) established that routine 1:1 protamine reversal after transfemoral TAVI reduces clinically relevant bleeding without meaningful anaphylaxis penalty (1.3% vs 0%, no deaths). The trial did not move death or major bleeding, so Toby Rogers' framing is fair: it changes minor-bleed physiology, not hard outcomes. Neither ACC/AHA 2020 nor ESC 2025 currently specify a protamine strategy; this is the first randomized answer. Separately, a single-center 1,476-patient series found routine femoral protection wire use associated with higher vascular complications (18.6% vs 10.8%, OR 0.52 for omission) — non-randomized, before-after design, but consistent with the direction protamine data are pushing: less instrumentation, cleaner closure. A 3-RCT meta-analysis (n=1,156) of PCI in TAVI candidates found no death or MI benefit, a stroke reduction (OR 0.68), and a bleeding-risk trend upward. Guideline context: ACC/AHA 2020 and ESC 2025 both defer to Heart Team judgment on pre-TAVI revascularization; this analysis argues for restraint, not reflex. The ATTR-CA systematic review (1,637 dual-diagnosis patients) reinforces that amyloid comorbidity does not preclude TAVI but predicts pacemaker, AKI, and late HF readmission — a risk-stratification finding, not a gatekeeping one. A 9,748-patient Ontario registry confirmed the durable operational lesson: Heart Team involvement and transfemoral-without-general-anesthesia are the QIs that track with better 1-year composite outcomes.
Mitral Valve (MitraClip, PASCAL, TMVR)
No pivotal mitral trial today, but the device pipeline moved. InnovHeart reported the first US Saturn transseptal TMVR implant, bringing the global cohort to 15 — early feasibility, no comparative data, and TMVR remains an unproven category where surgical replacement or repair still owns the evidence base. ACC/AHA 2020 and ESC 2025 both keep TMVI at Class IIb for degenerative MS with MAC in experienced centers; there is no guideline endorsement for TMVR in primary or secondary MR outside trials. A JACC Case Reports single-patient report of ultra-early TEER under VA-ECMO for post-infarction papillary muscle rupture is instructive but n=1; the surgical standard for acute papillary muscle rupture remains emergent MV replacement, and TEER in this setting is salvage, not therapy of first choice. Recall the guideline split still in play: ESC 2025 upgraded TEER for ventricular secondary MR to Class I based on COAPT 5-year, RESHAPE-HF2, and meta-analysis; ACC/AHA 2020 remains Class IIa. Nothing today shifts that gap.
Tricuspid Valve (TriClip, TTVR)
Medscape's ESC coverage reported transcatheter tricuspid repair reduced death and HF hospitalization in severe TR — the framing that, if borne out in the full publication, would push transcatheter TR therapy toward a mortality claim it has not previously owned. TRILUMINATE Pivotal at 2 years drove the ESC 2025 Class IIa recommendation on QoL and HF hospitalization endpoints, not mortality; Tri.Fr and TRISCEND II followed the same pattern. A mortality signal would be genuinely new. ACC/AHA 2020 has no transcatheter TR recommendation at all, so any positive readout widens the transatlantic gap. Surgical counterpoint: ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I and for asymptomatic primary TR with RV dilation to Class IIa, but the late-referral problem persists — patients arrive with RV failure and end-organ damage that neither surgery nor transcatheter can reverse. A separate contemporary review of failed tricuspid prostheses reinforces the Heart Team imperative: valve-in-valve TTVR shows favorable early success but durability beyond mid-term is unknown, especially in younger patients.
Surgical vs. Transcatheter Comparisons
No head-to-head trial today. The relevant surgical benchmark for today's TAVI periprocedural data is that SAVR carries its own bleeding and transfusion burden, and the POPular ACE TAVI protamine benefit narrows TAVI's already-favorable early-bleeding profile further. The redo case report of SAVR after TAVI degeneration in a prior David procedure is a reminder that lifetime-management planning — the ESC 2025 emphasis — is not theoretical. THV explantation carries 12-17% mortality in registry data, and the population entering their second or third valve intervention is growing. ACC/AHA 2020 age thresholds (<65 SAVR, >80 TAVI) and ESC 2025 thresholds (<70 SAVR if low-risk, ≥70 TAVI with tricuspid AV) remain the operative framework, and nothing today changes the durability calculus.
Device & Technology
Cardiovascular Business aggregated TAVR device news including Medtronic capital deployment into structural heart, new anchoring techniques, and large-annulus data. A bench comparison of classic BASILICA, balloon-assisted BASILICA, and the UNICORN technique advances leaflet-laceration options for coronary obstruction risk — bench data only, no clinical endpoints. CT-FFR feasibility in TAVI candidates (N=37) showed 88.5% accuracy vs invasive angiography for functionally significant CAD, with 13% of screened patients excluded for image quality — small, single-center, retrospective. Larger prospective validation is required before CT-FFR displaces catheter-based physiology in the pre-TAVI workup.
Regulatory & Policy
[NOTABLE] The FDA classified Boston Scientific's Infinion CX Lead recall as the most serious type, with 1,081 reported serious injuries and no deaths as of May 27, 2026. The recall involves unused inventory only; implanted devices are not affected. This is a spinal cord stimulator (chronic pain), not a structural heart device, but it lands on BSX at a moment when the stock is already down 35% over six months and materially widens the operational overhang for a company whose structural heart franchise (Acurate neo2, WATCHMAN) sits alongside its neuromodulation business.
Industry & Market
Medtronic announced partnerships and investments with Cornerstone Robotics and Pi-Cardia, funneling capital into robotics and structural heart per Citeline's Q1 analysis, with ablation driving the quarter. Pi-Cardia's ShortCut leaflet-modification device is directly relevant to the TAV-in-TAV and TAV-in-SAV lifetime-management problem the ESC 2025 flagged. InnovHeart's first US Saturn TMVR puts another private entrant into the transseptal TMVR race alongside Edwards' EVOQUE M and Abbott's Tendyne.
Financial Analysis
Boston Scientific's 35% six-month drawdown is the market signal that most demands clinical context, and today's FDA Class I Infinion CX recall does not help the tape even though it is a neuromodulation, not structural heart, issue. Edwards trades near the high end of its six-month range on continued TAVR volume and the growing tricuspid-therapy narrative, with Nykredit disclosing a fresh $20.6M position. Medtronic's beat and its structural heart / robotics capital deployment argue that the market is pricing MDT's pipeline conservatively at 14.5x forward earnings — the analyst target of $102.88 implies 10% upside. Anteris continues its 35% six-month rally on optimism around the DurAVR THV, though the company remains loss-making with a forward P/E of -5.5.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $89.78, down $1.04 (-1.15%); 6-month +5.35%
- Market cap $51.7B; trailing P/E 53.4; forward P/E 26.6; beta 0.85; 52-week $72.30–$96.29
- Analyst target $100.96 (26 analysts); consensus buy
- Next earnings 2026-10-29; EPS est $0.74; revenue est $1.68B
Edwards remains the pure-play structural heart name. TRISCEND II and the EVOQUE tricuspid franchise are the growth story; a favorable ESC readout on transcatheter TR mortality would extend the thesis. New institutional buying reported today.
Medtronic (MDT)
- Close: $93.10, up $0.92 (+1.00%); 6-month -0.93%
- Market cap $119.2B; trailing P/E 22.9; forward P/E 14.6; beta 0.57; 52-week $73.31–$106.33
- Analyst target $102.88 (25 analysts); consensus buy
- Next earnings 2026-11-17; EPS est $1.33; revenue est $9.48B
Q1 beat driven by ablation. Structural heart franchise (Evolut FX+, Intrepid TMVR pipeline) now receiving fresh capital via Pi-Cardia and Cornerstone Robotics investments. Forward P/E of 14.6 sits well below sector.
Abbott (ABT)
- Close: $108.79, down $1.68 (-1.52%); 6-month -2.52%
- Market cap $188.2B; trailing P/E 35.2; forward P/E 17.9; beta 0.59; 52-week $81.97–$137.49
- Analyst target $120.20 (25 analysts); consensus buy
- Next earnings 2026-10-14; EPS est $1.42; revenue est $12.99B
MitraClip and TriClip anchor the structural heart segment. The ESC 2025 Class I upgrade for TEER in ventricular SMR remains a durable tailwind; a positive transcatheter TR mortality readout would benefit TriClip.
Boston Scientific (BSX)
- Close: $46.95, down $1.42 (-2.94%); 6-month -34.98%
- Market cap $68.0B; trailing P/E 19.6; forward P/E 13.7; beta 0.57; 52-week $42.20–$109.50
- Analyst target $62.69 (29 analysts); consensus buy
- Next earnings 2026-10-28; EPS est $0.81; revenue est $5.26B
Down another 2.94% today after the Class I Infinion CX Lead recall. The recall is neuromodulation-only, but sentiment has broken. Analyst target implies substantial upside if the structural heart franchise (Acurate neo2, WATCHMAN) executes.
Anteris Technologies (AVR.AX)
- Close: A$12.00, up $0.06 (+0.50%); 6-month +34.83%
- Market cap A$1.2B; forward P/E -5.5; 52-week A$5.20–$15.47
- Analyst target A$13.00 (1 analyst)
DurAVR THV pivotal enrollment continues. The single-piece bovine tissue design targets the durability question that keeps SAVR in the guidelines for younger patients — a differentiated bet, but pre-pivotal and loss-making.
Private structural heart players (JenaValve, J Valve, Meril, InnovHeart) remain unlisted. InnovHeart's Saturn TMVR US first implant is the day's private-side milestone.
Outlook: Structural heart equities remain bifurcated. Edwards and Medtronic reflect the market's confidence in TAVR volume and expanding transcatheter mitral/tricuspid indications; Boston Scientific's drawdown reflects concentrated operational risk that has spread to sentiment. The ESC 2025 guideline expansions (TAVI to age 70, TEER Class I in ventricular SMR, transcatheter TR Class IIa) create the multi-year demand curve; execution and durability data will decide which names capture it.
Clinical Trial Updates
POPular ACE TAVI, PCI-in-TAVI meta-analysis, and the ESC-presented transcatheter TR mortality data are today's meaningful trial signals, covered above. A CNIC-reported EJHF paper found a diabetes drug (SGLT2i class, per context) reduced complications after AVR — the perioperative HF signal is consistent with EMPULSE/DAPA-HF-style benefits and would extend GDMT considerations into the immediate post-valve window.
Social & Conference Highlights
ESC Congress 2026 in Munich dominated the news cycle. POPular ACE TAVI was the periprocedural highlight; the transcatheter TR mortality read was the structural heart headline of the meeting. Discussant Nicole Karam's framing — "83% did not need protamine" — captured the persistent tension between routine and selective strategies in periprocedural care.
Looking ahead: The remainder of ESC Congress will produce the full journal publications behind today's headline readouts. Watch for the transcatheter TR mortality paper in NEJM or JACC, which would materially reinforce the ESC 2025 Class IIa recommendation and widen the transatlantic guideline gap.